<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01536691</url>
  </required_header>
  <id_info>
    <org_study_id>ROAD</org_study_id>
    <nct_id>NCT01536691</nct_id>
  </id_info>
  <brief_title>Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone</brief_title>
  <acronym>ROAD</acronym>
  <official_title>To Assess the Efficacy and Safety of Ramosetron, Aprepitant and Dexamethasone Therapy vs Ondansetron, Aprepitant and Dexamethasone Therapy for Preventing of Nausea and Vomiting in Highly Emetogenic Chemotherapy (ROAD Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korean Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Astellas Pharma Korea, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hallym University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of Ramosetron, Aprepitant and
      Dexamethasone therapy versus Ondansetron, Aprepitant and Dexamethasone therapy for preventing
      of nausea and vomiting in highly emetogenic chemotherapy (ROAD study):

      Prospective multicenter, randomized, single blinded, phase III study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the efficacy and safety of Ramosetron, Aprepitant and Dexamethasone therapy versus
      Ondansetron, Aprepitant and Dexamethasone therapy for preventing of nausea and vomiting in
      highly emetogenic chemotherapy (ROAD study):
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">February 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete response (CR)</measure>
    <time_frame>acute phase (within 24 hrs after onset of chemotherapy)</time_frame>
    <description>CR means no vomiting &amp; no rescue medication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete response</measure>
    <time_frame>during delayed phase and whole study period</time_frame>
    <description>Delayed phase means 'from day 2 to day 5' after onset of chemotherapty whole study period means 'from day 1 to day 5' after onset of chemotherapty (acute phase + delayed phase).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">338</enrollment>
  <condition>Cancer</condition>
  <condition>Malignancy</condition>
  <arm_group>
    <arm_group_label>ramosetron, aprepitant, dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ramosetron 0.3 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ondansetron, aprepitant, dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ondansetron 16 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ramosetron</intervention_name>
    <description>ramosetron 0.3 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4</description>
    <arm_group_label>ramosetron, aprepitant, dexamethasone</arm_group_label>
    <other_name>Nasea - ramosetron</other_name>
    <other_name>Emend - aprepitant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ondansetron</intervention_name>
    <description>ondansetron 16 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4</description>
    <arm_group_label>ondansetron, aprepitant, dexamethasone</arm_group_label>
    <other_name>zofran - ondansetron</other_name>
    <other_name>Emend - aprepitant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients diagnosed as malignancy who will be treated with highly emetogenic
             chemotherapeutic agents (NCCN guideline v1.0 2011 anti-emesis), over 20 years and both
             sex

          2. ECOG performance status 0-2

          3. Available oral administration of study drugs

          4. Patients must sign an informed consent indicating that they are aware of the
             investigational nature of the study in keeping with the policy of the hospital

        Exclusion Criteria:

          1. Severe Hypertension, severe Heart disease, kidney disease (serum creatinine &gt; 3
             mg/dl), liver disease (AST, ALT &gt; 3 times of upper normal range, ALP &gt; 2 times of
             upper normal range)

          2. Patients with GI obstruction, active gastric ulcer or other diseases that could
             provoke nausea and vomiting

          3. Patients who have nausea and vomiting within 1 week before chemotherapy

          4. Patients who should take steroid, antiemetics, pimozide, terfenadine, astemizole,
             cisapride, rifampin, carbamazepine, phenytoin, ketoconazole, itraconazole, nefazodone,
             troleandomycin, clarithromycin, ritonavir or nelfinavir for the treatment of other
             diseases

          5. Patients with brain tumor, brain metastasis or seizure

          6. Patients receiving chemotherapy within 12 months before enrollment

          7. Patients who need radiation therapy during study period or receiving radiation therapy
             within 2 weeks before chemotherapy

          8. Patients who have known allergy or severe side effect on study drugs

          9. Pregnant or lactating women, or women who wish to become pregnant

         10. Others whom the investigator judges inappropriate as subjects for this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sangwon Shin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyo Jung Kim, M.D. Ph.D.</last_name>
    <phone>82313803704</phone>
    <email>hemonc@hallym.or.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jinjoo Hong, R.N.</last_name>
    <phone>82232763517</phone>
    <email>datacenter7@kcsg.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hyo Jung Kim</name>
      <address>
        <city>Anyang</city>
        <state>Gyeonggi-do</state>
        <zip>431070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyo Jung Kim, M.D., Ph.D.</last_name>
      <phone>82313803704</phone>
      <email>hemonc@hallym.or.kr</email>
    </contact>
    <investigator>
      <last_name>Hyo Jung Kim, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2011</study_first_submitted>
  <study_first_submitted_qc>February 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2012</study_first_posted>
  <last_update_submitted>October 2, 2012</last_update_submitted>
  <last_update_submitted_qc>October 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ramosetron</keyword>
  <keyword>ondansetron</keyword>
  <keyword>aprepitant</keyword>
  <keyword>chemotherapy induced nausea &amp; vomiting</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Ramosetron</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

